Free Trial

atai Life Sciences (ATAI) Competitors

atai Life Sciences logo
$3.58 -0.17 (-4.41%)
As of 03:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ATAI vs. INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, and HRMY

Should you be buying atai Life Sciences stock or one of its competitors? The main competitors of atai Life Sciences include Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

atai Life Sciences vs. Its Competitors

atai Life Sciences (NASDAQ:ATAI) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

atai Life Sciences has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

28.4% of atai Life Sciences shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 26.8% of atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Indivior had 5 more articles in the media than atai Life Sciences. MarketBeat recorded 7 mentions for Indivior and 2 mentions for atai Life Sciences. atai Life Sciences' average media sentiment score of 1.17 beat Indivior's score of 0.41 indicating that atai Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
atai Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Indivior
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

atai Life Sciences has a net margin of 0.00% compared to Indivior's net margin of -4.02%. Indivior's return on equity of -97.29% beat atai Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
atai Life SciencesN/A -102.10% -77.55%
Indivior -4.02%-97.29%15.74%

atai Life Sciences presently has a consensus price target of $9.00, indicating a potential upside of 151.75%. Indivior has a consensus price target of $17.75, indicating a potential upside of 4.25%. Given atai Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe atai Life Sciences is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
atai Life Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50
Indivior
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

Indivior has higher revenue and earnings than atai Life Sciences. Indivior is trading at a lower price-to-earnings ratio than atai Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
atai Life Sciences$310K2,310.37-$149.27M-$0.91-3.93
Indivior$1.19BN/A$2M-$0.31-54.92

Summary

atai Life Sciences and Indivior tied by winning 8 of the 16 factors compared between the two stocks.

Get atai Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATAI vs. The Competition

Metricatai Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$718.22M$3.78B$5.72B$9.52B
Dividend YieldN/A1.33%4.60%3.99%
P/E Ratio-3.9432.7128.0720.02
Price / Sales2,310.37130.06462.58104.32
Price / CashN/A22.4036.5558.97
Price / Book5.184.398.645.90
Net Income-$149.27M$189.47M$3.24B$258.50M
7 Day Performance10.68%2.03%4.08%2.12%
1 Month Performance62.50%-3.43%10.68%12.62%
1 Year Performance126.27%-2.50%34.47%19.25%

atai Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATAI
atai Life Sciences
3.437 of 5 stars
$3.58
-4.4%
$9.00
+151.7%
+147.7%$718.22M$310K-3.9480Gap Up
INDV
Indivior
1.1562 of 5 stars
$15.62
+0.9%
$17.00
+8.9%
+54.5%$2.15B$1.17B-50.371,051News Coverage
Analyst Forecast
RXRX
Recursion Pharmaceuticals
1.4367 of 5 stars
$5.27
-0.3%
$7.00
+33.0%
-19.8%$2.14B$59.82M-2.97400
DNLI
Denali Therapeutics
4.2552 of 5 stars
$14.68
+1.1%
$33.71
+129.7%
-39.4%$2.13B$330.53M-5.50430News Coverage
Positive News
Upcoming Earnings
BEAM
Beam Therapeutics
2.2175 of 5 stars
$21.17
+0.0%
$48.75
+130.3%
-29.7%$2.13B$63.52M-4.59510Analyst Revision
KNSA
Kiniksa Pharmaceuticals International
3.4535 of 5 stars
$28.81
+2.6%
$39.33
+36.5%
+6.7%$2.10B$423.24M-115.26220News Coverage
BLTE
Belite Bio
1.7942 of 5 stars
$63.55
+0.5%
$96.67
+52.1%
+28.5%$2.02BN/A-46.7310High Trading Volume
CNTA
Centessa Pharmaceuticals
3.3153 of 5 stars
$15.05
+4.3%
$27.89
+85.3%
+51.2%$2.01B$15M-8.31200High Trading Volume
VCEL
Vericel
3.6702 of 5 stars
$39.89
-0.1%
$61.14
+53.3%
-24.2%$2.01B$238.54M1,329.98300News Coverage
Positive News
Upcoming Earnings
IRON
Disc Medicine
3.3594 of 5 stars
$57.82
+1.6%
$96.70
+67.2%
+36.0%$2.00BN/A-14.7530Gap Up
HRMY
Harmony Biosciences
4.7974 of 5 stars
$34.71
+2.1%
$51.33
+47.9%
+11.9%$1.99B$714.73M13.25200Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ATAI) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners